At a glance
ClinicalIndex Comparison RecordPhase 2Active· 154 enrolled
Drug / intervention
Irinotecan + Carboplatin +1 moredrug
Likely dose
Irinotecan + Carboplatin 90 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Irinotecan + Carboplatin and irinotecan + Carboplatin + erbitux for Metastatic Breast Cancer. Active but no longer recruiting, targeting 154 participants across 59 sites.
Detailed Summary
The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Pfizer
Timeline
Phase 2Active
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2005
First PostedNov 2005
Primary CompletionDec 2025
TodayJul 2026
Study CompletionDec 2026
First PostedNov 3, 2005
Enrollment StartJul 28, 2005
Primary CompletionDec 1, 2025
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 20.3 yearsPosted 20.7 years ago
Interventions
Irinotecan + Carboplatindrug
irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
irinotecan + Carboplatin + erbituxdrug
irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2